Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the ability of 23 novel biomarkers representing several pathophysiological pathways to improve the prediction of cardiovascular event ( CVE ) risk in patients with type 2 diabetes mellitus beyond traditional risk factors. Methods and Results: We used data from 1002 patients with type 2 diabetes mellitus from the Second Manifestations of ART ertial disease ( SMART ) study and 288 patients from the European Prospective Investigation into Cancer and Nutrition‐ NL ( EPIC ‐ NL ). The associations of 23 biomarkers (adiponectin, C‐reactive protein, epidermal‐type fatty acid binding protein, heart‐type fatty acid binding protein, basic fibroblast growth factor, soluble FMS‐like tyrosine kinase‐1, soluble intercellular adhesion molecule‐1 and ‐3, matrix metalloproteinase [MMP]‐1, MMP ‐3, MMP ‐9, N‐terminal prohormone of B‐type natriuretic peptide, osteopontin, osteonectin, osteocalcin, placental growth factor, serum amyloid A, E‐selectin, P‐selectin, tissue inhibitor of MMP‐1, thrombomodulin, soluble vascular cell adhesion molecule‐1, and vascular endothelial growth factor) with CVE risk were evaluated by using Cox proportional hazards analysis adjusting for traditional risk factors. The incremental predictive performance was assessed with use of the c‐statistic and net reclassification index ( NRI ; continuous and based on 10‐year risk strata 0–10%, 10–20%, 20–30%, >30%). A multimarker model was constructed comprising those biomarkers that improved predictive performance in both cohorts. N‐terminal prohormone of B‐type natriuretic peptide, osteopontin, and MMP ‐3 were the only biomarkers significantly associated with an increased risk of CVE and improved predictive performance in both cohorts. In SMART , the combination of these biomarkers increased the c‐statistic with 0.03 (95% CI 0.01–0.05), and the continuous NRI was 0.37 (95% CI 0.21–0.52). In EPIC ‐ NL , the multimarker model increased the c‐statistic with 0.03 (95% CI 0.00–0.03), and the continuous NRI was 0.44 (95% CI 0.23–0.66). Based on risk strata, the NRI was 0.12 (95% CI 0.03–0.21) in SMART and 0.07 (95% CI −0.04–0.17) in EPIC‐NL. Conclusions: Of the 23 evaluated biomarkers from different pathophysiological pathways, N‐terminal prohormone of B‐type natriuretic peptide, osteopontin, MMP ‐3, and their combination improved CVE risk prediction in 2 separate cohorts of patients with type 2 diabetes mellitus beyond traditional risk factors. However, the number of patients reclassified to a different risk stratum was limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“T ype 2 diabetes mellitus is a growing worldwide health problem, with an estimated 592 million people living with diabetes mellitus by 2035.(1) Patients with diabetes mellitus are at 2- to 4-fold increased risk of cardiovascular events (CVEs).”
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Flexible Imputation of Missing Data
van Buuren, S. (2012) · doi:10.1201/b11826 · Cited by 2,022
C-reactive protein, fibrinogen, and cardiovascular disease prediction
The Emerging Risk Factors Collaboration (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107477 · Cited by 1,150
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 1×
“The base model included predictors of the United Kingdom Prospective Diabetes Study algorithm (age at diabetes diagnosis, duration of diagnosed diabetes, sex, smoking, glycated hemoglobin (HbA1c), systolic blood pressure, total cholesterol/high-density lipoprotein (HDL) cholesterol ratio), and 2 additional variables (…”
Leening, M. J. G., Vedder, M. M., Witteman, J. C. M., Pencina, M. J., & Steyerberg, E. W. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1522 · Cited by 594
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors
Howard, B. V., Best, L. G., Galloway, J. M., Howard, W. J., Jones, K., Lee, E. T., Ratner, R. E., Resnick, H. E., & Devereux, R. B. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1299 · Cited by 180 · cited 1×
“Recent studies indicated that there actually is a wide distribution of risk depending on diabetes mellitus duration, severity, and concomitant risk factors.(4,5) Accurate cardiovascular risk stratification can help clinicians to identify low-risk patients for whom treatment could be postponed or high-risk patients for…”
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
Gerstein, H. C., Paré, G., McQueen, M. J., Haenel, H., Lee, S. F., Pogue, J., Maggioni, A. P., Yusuf, S., & Hess, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015744 · Cited by 69 · cited 2×
“The present study is in line with findings from 2 recent reports showing similar directional associations for NT-proBNP, whereas the predictive usefulness of MMP-3 and osteopontin were equivocal, partly due to a shorter follow-up duration and different patient population (eg, also including patients with impaired fast…”
Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes
on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3535-6 · Cited by 66 · cited 1×
“The present study is in line with findings from 2 recent reports showing similar directional associations for NT-proBNP, whereas the predictive usefulness of MMP-3 and osteopontin were equivocal, partly due to a shorter follow-up duration and different patient population (eg, also including patients with impaired fast…”
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Seferović, P., Farmakis, D., Bayes-Genis, A., Ben Gal, T., Böhm, M., Chioncel, O., Ferrari, R., Filippatos, G., Hill, L., Jankowska, E., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2575 · Cited by 24
Cardiovascular biomarkers in clinical studies of type 2 diabetes
Baldassarre, M. P. A., Andersen, A., Consoli, A., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13247 · Cited by 22
“to improve predictive performance among 23 biomarkers evaluated in patients with T2D.(17) In patients with T2D without symptoms related to CVD, Ballo et al.”
Background
Metadata
- Authors
- van der Leeuw, J., Beulens, J. W. J., van Dieren, S., Schalkwijk, C. G., Glatz, J. F. C., Hofker, M. H., Verschuren, W. M. M., Boer, J. M. A., van der Graaf, Y., Visseren, F. L. J., Peelen, L. M., & van der Schouw, Y. T.
- Venue
- Journal of the American Heart Association
- Published
- 2016-06-13
- Volume
- 5
- Issue
- 6
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2417783437
- Cited by
- 77
- References
- 13
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.